| scholarly article | Q13442814 |
| P2093 | author name string | S S Pedersen | |
| T Jensen | |||
| P Osterhammel | |||
| D Osterhammel | |||
| P2860 | cites work | Are measurements of urine enzymes useful during aminoglycoside therapy? | Q71572006 |
| Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin | Q72551535 | ||
| Attenuation of experimental tobramycin nephrotoxicity by ticarcillin | Q28362582 | ||
| Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin | Q28366502 | ||
| Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients | Q28367851 | ||
| Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982 | Q34055509 | ||
| Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection | Q34056063 | ||
| Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin | Q34056699 | ||
| Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction | Q39846012 | ||
| Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease | Q39856815 | ||
| Recent otological evaluation of aminoglycoside antibiotics | Q40170712 | ||
| Acute interstitial nephritis due to drugs: Review of the literature with a report of nine cases | Q40350225 | ||
| Protection from Gentamicin Nephrotoxicity by Cephalothin and Carbenicillin | Q40619774 | ||
| Antibiotic combination-associated nephrotoxicity in granulocytopenic patients with cancer | Q40849637 | ||
| Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis | Q43431316 | ||
| An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre | Q44021808 | ||
| Aminoglycoside clearance in patients with cystic fibrosis | Q44379780 | ||
| A quasi-free-field transducer system for high-frequency audiometry | Q47625183 | ||
| Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. | Q50589543 | ||
| Drug-induced ototoxicity. | Q50605940 | ||
| Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis | Q50611182 | ||
| High-Frequency Audiometry: Age and sex variations | Q50613669 | ||
| Good antimicrobial prescribing. Aminoglycosides | Q54513584 | ||
| Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy | Q67252347 | ||
| Tobramycin therapy of pulmonary infections in patients with cystic fibrosis | Q67292345 | ||
| Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin | Q69888145 | ||
| Dosing implications of altered gentamicin disposition in patients with cystic fibrosis | Q70214647 | ||
| Pharmacokinetics of tobramycin in cystic fibrosis | Q70274688 | ||
| The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity | Q70480733 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 594-9 | |
| P577 | publication date | 1987-04-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis | |
| P478 | volume | 31 |
| Q89532597 | A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis |
| Q41474199 | Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients |
| Q50435277 | Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions |
| Q38676819 | Aminoglycoside-induced hearing loss in humans |
| Q38795059 | Aminoglycoside-induced nephrotoxicity in children |
| Q39066887 | Changes in the inner ear structures in cystic fibrosis patients |
| Q50564526 | Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). |
| Q37977706 | Cystic fibrosis, pathophysiological and clinical aspects |
| Q40354089 | Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients. |
| Q40578214 | Mechanism of action of antibiotics in chronic pulmonary pseudomonas infection. |
| Q33775991 | Minimisation of aminoglycoside toxicity in patients with cystic fibrosis |
| Q50437553 | Minimizing the toxicity of aminoglycosides in cystic fibrosis |
| Q45991071 | No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. |
| Q33982886 | Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. |
| Q38239743 | Once-daily aminoglycoside administration: new strategies for an old drug |
| Q37263821 | Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation |
| Q35121949 | Pharmacokinetics of vancomycin in adult cystic fibrosis patients. |
| Q35191390 | Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms |
| Q34111815 | Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis |
| Q37591440 | Renal dysfunction in cystic fibrosis: is there cause for concern? |
| Q35682983 | Risk factors for chronic kidney disease in adults with cystic fibrosis. |
| Q30479961 | Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis |
| Q88376487 | Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms |
| Q54043285 | [Antibiotic therapy in cystic fibrosis. II Antibiotic strategy] |
Search more.